Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. Differential immunodominance hierarchy of CD8+ T cell responses in HLA-B*27:05 and B*27:02-mediated control of HIV-1 infection
 
research article

Differential immunodominance hierarchy of CD8+ T cell responses in HLA-B27:05 and B27:02-mediated control of HIV-1 infection

Adland, Emily
•
Hill, Matilda
•
Lavandier, Nora
Show more
2018
Journal of Virology

The well-characterised association between HLA-B27:05 and protection against HIV disease progression has been linked to immunodominant HLA-B27:05-restricted CD8+ T-cell responses towards the conserved Gag 263-272 ('KK10') and Pol 901-909 'KY9' epitopes. We here studied the impact of the 3 amino acid differences between HLA-B27:05 and the closely-related HLA-B27:02 on the HIV-specific CD8+ T-cell response hierarchy and on immune control of HIV. Genetic epidemiological data indicate that both HLA-B27:02 and HLA-B27:05 associate with slower disease progression and lower viral loads. The effect of HLA-B27:02 appears consistently stronger than that of HLA-B27:05. In contrast to HLA-B27:05, the immunodominant HIV-specific HLA-B27:02-restricted CD8+ T-cell response is to a Nef epitope (residues 142-150, 'VW9'), with Pol-KY9 subdominant and Gag-KK10 further subdominant. This selection was driven by structural differences in the F-pocket, mediated by a polymorphism between these two HLA alleles at position 81. Analysis of autologous virus sequences showed that in HLA-B27:02-positive subjects all three of these CD8+ T-cell responses impose selection pressure on the virus, whereas in HLA-B27:05-positive subjects there is no Nef-VW9-mediated selection pressure. These studies demonstrate that HLA-B27:02 mediates protection against HIV disease progression that is at least as strong or stronger than that mediated by HLA-B27:05. In combination with the protective Gag-KK10 and Pol-KY9 CD8+ T-cell responses that dominate HIV-specific CD8+ T-cell activity in HLA-B27:05-positive subjects, a Nef-VW9-specific response is additionally present and immunodominant in HLA-B27:02-positive subjects, mediated through a polymorphism at residue 81 in the F-pocket, that contributes to selection pressure against HIV.IMPORTANCE CD8+ T-cells play a central role in successful control of HIV infection, and have the potential also to mediate the eradication of viral reservoirs of infection. The principal means by which 'protective' HLA class I molecules, such as HLA-B27:05 and HLA-B57:01, slow HIV disease progression, is believed to be via the particular HIV-specific CD8+ T cell responses restricted by those alleles. We focus here on HLA-B27:05, one of the best-characterised 'protective' HLA molecules, and the closely-related HLA-B27:02, which differs by only 3 amino acids, and which has not been well-studied in relation to control of HIV infection. We show that HLA-B27:02 is also protective against HIV disease progression, but the CD8+ T-cell immunodominance hierarchy of HLA-B27:02 differs strikingly from that of HLA-B27:05. These findings indicate that the immunodominant HLA-B27:02-restricted Nef response adds to protection mediated by the Gag and Pol specificities that dominate anti-HIV CD8+ T-cell activity in HLA-B*27:05-positive subjects.

  • Files
  • Details
  • Metrics
Loading...
Thumbnail Image
Name

e01685-17.full.pdf

Type

Publisher's Version

Version

Published version

Access type

openaccess

License Condition

CC BY

Size

1.99 MB

Format

Adobe PDF

Checksum (MD5)

fb6e91d241bff06a8538b2643cf6b378

Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés